Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HL-7037 is a novel cyclic peptide radiopharmaceutical candidate designed to target glypican-3 (GPC3), which is highly upregulated in hepatocellular carcinoma (HCC) but has limited expression in healthy tissues. Developed by HighsLab Therapeutics, HL-7037 is designed to achieve selective GPC3 binding, tumor-specific uptake, and long-term tumor retention. It can be chelated with radiometal isotopes such as Gallium-68 (68Ga) for positron emission tomography (PET) imaging, or Lutetium-177 (177Lu) and Actinium-225 (225Ac) for targeted radionuclide therapy. Preclinical studies in HepG2 tumor-bearing mouse models have demonstrated high tumor-specific uptake and significant tumor growth inhibition.
| Indication | Highest phase | Status |
|---|---|---|
| hepatocellular carcinoma (HCC) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: hepatocellular carcinoma (HCC)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HL-7037.
Work on HL-7037? Claim this page to correct or add information. Claim this page